Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy. METHODS: We conducted a randomized, controlled trial involving patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both. Patients had to have an LDL cholesterol level of at least 70 mg per deciliter while they were receiving maximally tolerated statin therapy with or without additional lipid-lowering therapy. (Maximally tolerated statin therapy was defined as the highest intensity statin regimen that a patient was able to maintain, as determined by the investigator.) Patients were randomly assigned in a 2:1 ratio to receive bempedoic acid or placebo. The primary end point was safety, and the principal secondary end point (principal efficacy end point) was the percentage change in the LDL cholesterol level at week 12 of 52 weeks. RESULTS: The trial involved 2230 patients, of whom 1488 were assigned to receive bempedoic acid and 742 to receive placebo. The mean (±SD) LDL cholesterol level at baseline was 103.2±29.4 mg per deciliter. The incidence of adverse events (1167 of 1487 patients [78.5%] in the bempedoic acid group and 584 of 742 [78.7%] in the placebo group) and serious adverse events (216 patients [14.5%] and 104 [14.0%], respectively) did not differ substantially between the two groups during the intervention period, but the incidence of adverse events leading to discontinuation of the regimen was higher in the bempedoic acid group than in the placebo group (162 patients [10.9%] vs. 53 [7.1%]), as was the incidence of gout (18 patients [1.2%] vs. 2 [0.3%]). At week 12, bempedoic acid reduced the mean LDL cholesterol level by 19.2 mg per deciliter, representing a change of -16.5% from baseline (difference vs. placebo in change from baseline, -18.1 percentage points; 95% confidence interval, -20.0 to -16.1; P<0.001). Safety and efficacy findings were consistent, regardless of the intensity of background statin therapy. CONCLUSIONS: In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CLEAR Harmony trial assessed bempedoic acid’s safety and efficacy in 2230 statin-treated patients with atherosclerosis or HeFH compared with placebo [130]. Relative to placebo, bempedoic acid reduced LDL-C by − 16%, non-HDL-C by − 13%, total cholesterol by − 11%, ApoB-100 by − 12% and hsCRP by − 22%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“The incidence of adverse events was similar across both interventional groups, yet a higher percentage discounted treatment with bempedoic acid than placebo (10.9% versus 7.1%). Gout was more frequently observed among patients treated with bempedoic acid (1.2% versus 0.3%).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“Safety findings in the real-world setting were generally aligned with those reported in RCTs and meta-analyses [[12], [13], [14], [15],17,18], although reporting was limited and inconsistently captured.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
A peroxidase-coupled method for the colorimetric determination of serum triglycerides.
McGowan, M. W., Artiss, J. D., Strandbergh, D. R., & Zak, B. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.538 · Cited by 1,298
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Self-citationBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Self-citationMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D. R., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 342
Self-citation
Cited by
Items 401–500 of 807
Seijas‐Amigo, J., Cordero, A., Olmo, R. F., Quiroga, G. A. C., Fácila, L., Salgado‐Barreira, Á., Reyes-Santías, F., Romero‐Menor, C., Rondán, J., Rodríguez‐Mañero, M., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001365 · Cited by 8
Jadhav, S. B., Amore, B. M., Bockbrader, H. N., Crass, R. L., Chapel, S. H., Sasiela, W. J., & Emery, M. G. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09864-w · Cited by 9
Wittlinger, T., Schwaab, B., Völler, H., Bongarth, C., Heinze, V., Eckrich, K., Guha, M., Richter, M., & Schlitt, A. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8090105 · Cited by 10
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
Interindividual variability in statin pharmacokinetics and effects of drug transporters
Hirota, T., & Ieiri, I. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2305746 · Cited by 10
“On the other hand, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo [29].”
BackgroundAn Update on New Cholesterol Inhibitor: Bempedoic Acid
Kulshreshtha, M. (2021) · Current Cardiology Reviews · doi:10.2174/1573403x17666211214111658 · Cited by 7
A Nutrient-Based Cellular Model to Characterize Acetylation-Dependent Protein-Protein Interactions
Loehr, J., Tchara, P.-E. K., Gonthier, K., Noufi, C., Linteau, N., Audet‐Walsh, É., & Lambert, J. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.831758 · Cited by 7
“In a trial involving over 2,200 patients, ETC-1002 treatment did not lead to higher incidence of overall adverse events when combined with statin therapy (Ray et al., 2019).”
BackgroundNew Trends and Therapies for Familial Hypercholesterolemia
Alnouri, F., & Santos, R. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226638 · Cited by 8
“At 52 weeks, BA did not result in higher incident of adverse effects and LDL-C lowering effects were maintained [75].”
BackgroundSchiele, F., Catapano, A. L., Caterina, R. D., Laufs, U., Jukema, J. W., Zaman, A., & Sionís, A. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad119 · Cited by 15
Self-citationAbrahams, T., & Nicholls, S. J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2292039 · Cited by 8
“In clinical trials, bempedoic acid has demonstrated significant reductions in LDL-C levels [32] and more recently demonstrated to reduce the rate of cardiovascular events in high risk patients with statin intolerance [12].”
BackgroundLi, Y., Gao, H., Zhao, J., Ma, L., & Hu, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297854 · Cited by 9
Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation
Zeng, W., & Tomlinson, B. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2424411 · Cited by 8
“Likewise, in the CLEAR Harmony trial in patients receiving maximally tolerated statin therapy, bempedoic acid 180 mg daily lowered LDL-C levels at week 12 by 18.1% compared with placebo [54].”
InfluentialZhu, L., Zhou, K., Ma, M., Yao, L., Zhang, Y. L., Li, H., Du, C., & Yang, X. M. (2022) · Journal of Immunology Research · doi:10.1155/2022/1590717 · Cited by 7
“On the other hand, ACLY inhibitors have shown effectiveness as cholesterol-lowering drugs in clinical trials of hypercholesterolemia [39, 40].”
A stepwise approach to prescribing novel lipid-lowering medications
Kakavand, H., Aghakouchakzadeh, M., Shahi, A., Virani, S. S., Dixon, D. L., Tassell, B. W. V., & Talasaz, A. H. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.003 · Cited by 7
Mohan, G. V. K., Chenna, V. S. H., Tirumandyam, G., Mian, A. R., Rashid, A., & Saleem, F. (2023) · Cureus · doi:10.7759/cureus.38662 · Cited by 11
“Goldberg et al [12] 2019 Maximally Tolerated Statins Bempedoic Acid 522 12 Months 64.4 63.7 100 Placebo 257 Nissen et al [13] 2023 Statin intolerant patients Bempedoic Acid 6992 60 Months 65.5 51.8 22.7 Placebo 6978 Ray et al [14] 2019 Maximally Tolerated Statins Bempedoic Acid 1487 12 Months 66.3 68.9 100 Placebo 742…”
BackgroundInfluentialAtherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 11
Guijarro, C., & Camafort, M. (2019) · Revista Clínica Española · doi:10.1016/j.rce.2019.05.010 · Cited by 9
Feldman, D. I., Dudum, R., Alfaddagh, A., Marvel, F. A., Michos, E. D., Blumenthal, R. S., & Martin, S. S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100027 · Cited by 7
“Two studies published in 2019, the CLEAR HARMONY and CLEAR WISDOM trials, demonstrated that addition of bempedoic acid to maximally tolerated statin decreases LDLC by ~15–17% and also reduced hsCRP [20,21].”
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
Self-citationNew players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
Ruscica, M., Sirtori, C. R., Ferri, N., & Corsini, A. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab090 · Cited by 7
“2% at Weeks 12, 24, and 52, respectively.(6) In the CLEAR Wisdom, LDL-C levels were absolutely reduced by 17.”
BackgroundEmerging Strategies for the Management of Atherogenic Dyslipidaemia
Agarwala, A., & Shapiro, M. D. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.16 · Cited by 7
Lower LDL is better – can this be achieved with CETP inhibition therapy?
Rashid, S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1715797 · Cited by 7
Hamayal, M., Shahid, W., Akhtar, C. H., Shekiba, F., Iftikhar, I., Tahir, M. D., Awwab, M., Hussain, S., Naeem, S., & Hafeez, M. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2388478 · Cited by 6
Yamashita, S., Fujita, H., Yokota, D., Isogai, Y., & Kitamoto, R. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65336 · Cited by 6
“A long-term study conducted overseas with the primary endpoint of safety in patients with an inadequate response to secondary prevention and statins showed no significant difference in the incidence of adverse events in the bempedoic acid 180 mg group relative to the placebo group 19) .”
InfluentialAshraf, T., Devi, N., Aradhna, F., Devi, S., Nancy, F., Kumar, A., Ameer, F., Absar, F., Kumar, L., Kumar, S., et al. (2025) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000003505 · Cited by 6
“Bempedoic acid, an ATP-citrate-lyase inhibitor, produced small TG reductions (–5.1% and -4.4%, respectively) alongside 17%–18% LDL-C lowering [ 52 , 53 ] .”
InfluentialRole of bempedoic acid in patients with hypercholesterolemia and statin intolerance
Girardi, J. M., & do Couto, A. A. (2023) · Journal Archives of Health · doi:10.46919/archv4n1-011 · Cited by 7
Calabrò, P., Spaccarotella, C., Cesaro, A., Andò, G., Piccolo, R., Rosa, S. D., Zimarino, M., Mancone, M., Gragnano, F., Moscarella, E., et al. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001440 · Cited by 6
White, R. T., Sankey, K. H., & Nawarskas, J. J. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000522 · Cited by 6
Familial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments
Mirzai, S., Chevli, P. A., Rikhi, R. R., & Shapiro, M. D. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411311 · Cited by 11
Is there a role for earlier use of combination therapy?
Revankar, S., Park, J. K., Satish, P., & Agarwala, A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100639 · Cited by 6
“By week 12, there was mean LDL-C reduction of 19.2 mg/dL (0.50 mmol/L) with continued, minimally attenuated effects, until at least week 52 of treatment [56].”
BackgroundInfluentialAfzal, M. A., Khalid, N., Abdullah, M., Haiy, A. U., Hassan, M. A., Sana, H., Elkattawy, S., Malik, A. A., Michael, P., Vasudev, R., et al. (2024) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1305 · Cited by 11
Effects of statins beyond lipid-lowering agents in ART-treated HIV infection
Mehraj, V., Chen, J., & Routy, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1339338 · Cited by 9
Wu, Y., Zhao, Z., Yang, M., He, Y., Zang, Y., Li, J., Hu, J., & Xiong, J. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106018 · Cited by 6
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Cardiovascular risk management beyond statins: review of new therapies available in Italy
Capuozzo, M., Ottaiano, A., Cinque, C., Farace, S., & Ferrara, F. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00660-0 · Cited by 8
“In this study, 90% of participants reached target LDL-C levels ( 70 mg/dL), and 95% experienced reductions of ≥ 50% [56, 57].”
Bempedoic acid for the treatment of hypercholesterolemia
Yang, J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1782744 · Cited by 6
Alam, U., Al-Bazz, D. Y., & Soran, H. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01070-6 · Cited by 6
Deo, S. V., Ueda, P., Sheikh, M. A., Altarabsheh, S. E., Elgudin, Y. E., Rubelowsky, J. J., CMOLIK, B. L., Hawkins, N., McAllister, D., Ruel, M., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001374 · Cited by 6
Patti, G., Cavallari, I., Cesaro, A., Gragnano, F., Riva, L., Fimiani, F., Cuccia, C., Fresco, C., Calabrò, P., Leonardi, S., et al. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107137 · Cited by 6
Sell, J. K., & Nunez, J. J. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197679098.003.0039 · Cited by 6
Alunno, A., Carubbi, F., Campanozzi, E., Bellisario, F., Schoones, J. W., Mariani, F. M., Ruscio, E. D., Altieri, P., & Ferri, C. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1234601 · Cited by 6
Targeting ATP citrate lyase to reduce LDL cholesterol
Huynh, K. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0201-6 · Cited by 6
ATP-citrate lyase: a driver of metabolism and histone acetylation
Orsó, E., & Burkhardt, R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000719 · Cited by 9
Statistical Methods for cis-Mendelian RandomizationPreprint
Gkatzionis, A., Burgess, S., & Newcombe, P. J. (2021) · arXiv (Cornell University) · Cited by 8
Li, B., Zhang, J., Huang, A., Chen, Y., & Wei, Q. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132305 · Cited by 7
Ferrari, R., Gowdak, L. H. W., Padilla, F., Quek, D. K., Ray, S., Rosano, G. M. C., Indolfi, C., & Filardi, P. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041161 · Cited by 11
“For patients who are intolerant to statins, bempedoic acid should be considered [22,23].”
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Khan, S., Hassan, M. Z., Hussain, M. S., Dhedhi, H. A. A., Fatima, W., Nawaz, J., Ahsan, A., Pirih, F. N. U., Khalid, N., Qaisar, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-29224-7 · Cited by 6
White, R. T., Ansong, B. O., & Cowart, K. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.014 · Cited by 5
Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy
Krátký, V., Valeriánová, A., Hrušková, Z., Tesař, V., & Malík, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01191-w · Cited by 6
“Administering bempe-doic acid to patients already on statins is safe and leads to a significant reduction in LDL levels [56].”
Qureshi, Z. A., Khanzada, M., Safi, A., Fatima, E., Altaf, F., & Vittorio, T. J. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001945 · Cited by 6
“Bempedoic acid is an oral inhibitor of adenosine triphosphate citrate lyase, an enzyme of the cholesterol synthesis pathway [73] .”
BackgroundRajendran, Y., Nandhakumar, M., Eerike, M., Kondampati, N., Mali, K. R., Chalissery, L. F., Konda, V. G. R., & Nagireddy, U. M. (2024) · Cureus · doi:10.7759/cureus.69900 · Cited by 8
“This could be due to a larger sample size (n=2230) or due to the inclusion of patients with ASCVD [14].”
BackgroundTreatment of heterozygous familial hypercholesterolemia: what does the future hold?
Polychronopoulos, G., & Τζιόμαλος, Κ. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1839417 · Cited by 5
“The incidence of adverse events did not differ between the bempedoic acid and placebo groups regardless of the intensity of background statin treatment [37].”
BackgroundDiagnostik und Therapie von statinassoziierten Muskelsymptomen
Kassner, U., Grunwald, S. A., Spira, D., Buchmann, N., Bobbert, T., Gazzerro, E., Hollstein, T., Spuler, S., & Steinhagen‐Thiessen, E. (2021) · Der Internist · doi:10.1007/s00108-021-01059-0 · Cited by 5
Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
Parhofer, K. G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00971-y · Cited by 6
Bempedoic Acid: A New Tool for LDL-Cholesterol Control in Patients with Coronary Artery Disease
Bilato, C., Sesti, G., & Averna, M. R. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305156 · Cited by 6
“Study Duration Population Treatment groups (n) LDL-C reduction at 12 weeks (BA versus placebo) Muscle symptoms (BA versus placebo) CLEAR Harmony [9] 52 weeks ASCVD and/or HeFH patients with LDL-C ≥70 mg/dL in maximally tolerated statin with or without other LLT BA (n = 1488) –18.1% 95% CI, –20.0, –16.1 13.1% vs 10.1%…”
MethodInfluentialUpdate on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4
Pinsdorf, D., Messiha, D., Petrikhovich, O., Bahar, M., Steinmetz, M., Mahabadi, A. A., Dykun, I., Lortz, J., Rassaf, T., & Rammos, C. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.100 · Cited by 5
Lipid Metabolic Regulatory Crosstalk Between Cancer Cells and Tumor-Associated Macrophages
Liu, S., Shen, Y., Yin, L., Liu, J., & Zu, X. (2023) · DNA and Cell Biology · doi:10.1089/dna.2023.0071 · Cited by 6
“Bempedoic acid was approved by the Food and Drug Administration for lowering lipid levels in 2020 (Ray et al., 2019).”
Ju, Z., Guan, X., Zhang, B., Wang, J., Jin, X., Zhao, Y., & Li, B. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00606-4 · Cited by 4
“When used alone or in combination with ezetimibe, bempedoic acid can achieve atherosclerosis treatment through a dual pathway of cholesterol and high-sensitivity C-reactive protein (CRP) lowering [9–12].”
BackgroundBempedoic acid: a new player for statin-intolerant patients and beyond
Giordano, S. A., Spaccarotella, C., Esposito, G., & Indolfi, C. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000853 · Cited by 5
Lipid clinical trials with special reference to Indian population
Aseem Basha, M., & Ramakrishnan, S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.02.003 · Cited by 7
Espadas, I., Cáliz‐Molina, M. Á., López‐Fernández‐Sobrino, R., Panadero‐Morón, C., Sola‐García, A., Soriano‐Navarro, M., Martínez‐Force, E., Venegas‐Calerón, M., Salas, J. J., Martín, F., et al. (2024) · Aging Cell · doi:10.1111/acel.14205 · Cited by 5
“…and diabetes (Hatzivassiliou et al., 2005; Morrow et al., 2022; Sanjay et al., 2021; Verrelli et al., 2022), and the ACLY inhibitor Bemp has been shown to be safe and effective lowering circulating cholesterol levels in the clinic (Pinkosky et al., 2013; Ray et al., 2019; Ruscica et al., 2022).”
BackgroundNicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 10
Review of Recent Literature and Updates in Nonstatin Cholesterol Management
Wang, E. M., Asias-Dinh, B. D., & Rosario, N. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.001 · Cited by 7
Gillard, K. K., Bloedon, L. T., Grady-Benson, J. C., Edwards, A., Fahy, S., Sasiela, W. J., Louie, M. J., & Thompson, P. D. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00374-5 · Cited by 7
Self-citationRamachandran, S., Maarouf, A., Mitchell, K., Avades, T., Smith, P., Boulton, L., Kelly, J., Vekaria, N., & Hughes, E. (2024) · Drugs in Context · doi:10.7573/dic.2024-2-4 · Cited by 5
“The finding that 31% of patients in this audit had FH is considerably higher than observed in some clinical trials, 16 and is likely due to the classification of patients included in this secondary care cohort as being at high risk.”
ResultMaimaitituersun, G., Jureti, S., Zheng, Y., Zhou, Y., Li, M., Wei, M., Liu, Z., Jin, M., & Fu, Z.-Y. (2025) · PeerJ · doi:10.7717/peerj.19344 · Cited by 5
“While past discussions ( Crea, 2022 ; Ray et al., 2019 ; Ballantyne et al., 2023 ) on lipid management have focused on LDL-C treatment, potentially overlooking high-risk ASCVD individuals ( Björnson et al., 2023 ), dyslipidemia remains a potential target for reducing CVD incidence.”
Guijarro, C., & Camafort, M. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.05.005 · Cited by 5
Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States
Maki, K. C., Benes, L. B., & Dicklin, M. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_16 · Cited by 8
Tay, S., Abdulnabi, S., Saffaf, O., Harroun, N., Yang, C. Y., Semenkovich, C. F., & Zayed, M. A. (2021) · Clinical Diabetes · doi:10.2337/cd21-0019 · Cited by 8
Hammoud, A., & Shapiro, M. D. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.013 · Cited by 6
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
Parham, J. S., & Goldberg, A. C. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01036-4 · Cited by 6
Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach
Grant, J. K., Snow, S. C., Kelsey, M. D., Rymer, J. A., Schaffer, A. E., Patel, M. R., McGarrah, R. W., Pagidipati, N. J., & Shah, N. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01751-z · Cited by 5
Troncoso, J. Á., Carrasco-Molina, S., Robles‐Marhuenda, Á., Robles, E. M., & Blanco, J. J. R. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.05.011 · Cited by 5
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
ALGhasab, N. S., Fogacci, F., Арманович, А. А., & Cicero, A. F. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406270 · Cited by 5
Empleo del ácido bempedoico en los pacientes con dislipemia. Una aproximación práctica
Escobar, C., Barrios, V., Ariza, A., Campuzano, R., Martínez, J. M. G., & Mostaza, J. M. (2021) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(21)00005-4 · Cited by 7
Grassi, G. M., Pinto, R. D., Rosei, C. A., Agnoletti, D., Borghi, C., Cicero, A. F. G., Ciuceis, C. D., Desideri, G., Grassi, D., Muiesan, M. L., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00501-6 · Cited by 9
“The CLEAR Wisdom and CLEAR Harmony studies then confirmed the cholesterol-lowering effect of bempedoic acid in patients at high cardiovascular risk with manifest atherosclerotic disease, heterozygous familial hypercholesterolemia or both conditions [49, 50].”
BackgroundFeldman, D. I., Dudum, R., & Blumenthal, R. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_8 · Cited by 12
Quantitative Sub-Cellular Acyl-Coa Analysis Reveals Distinct Nuclear RegulationPreprint
Trefely, S., Huber, K., Liu, J., Noji, M., Stransky, S., Singh, J. P., Doan, M. T., Lovell, C. D., von Krusenstiern, E. V., Jiang, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3885983 · Cited by 5
Reed, S. D., Sutphin, J., Gonzalez, J. M., Wallace, M. J., Stephenson, J. J., Electricwala, B., Bosworth, H. B., & Pagidipati, N. (2025) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.011804 · Cited by 4
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 6
“In patients receiving the maximum tolerated statin dose or those who were statin intolerant, bempedoic acid led to a 16.5–21.1% reduction in LDL cholesterol compared to placebo, which was accompanied by a 13% reduction in MACE [264,265].”
InfluentialKhattak, S., Ochoa-Ferraro, A. F., Khan, N., George, S., Khan, S. Q., Townend, J., Dawson, C., & Thomas, M. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227946 · Cited by 6
“Our study showed that bempedoic acid reduced plasma LDL-C levels by approximately 35%, a greater reduction than the 18% reported in clinical trials [12,26].”
Rossi, R., Nouri, A., Akman, Z., Nezhad, S. A., Damluji, A. A., & Nanna, M. G. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02329-1 · Cited by 5
“These RCTs showed that bempedoic acid lowered LDL cholesterol levels without increasing the overall incidence of adverse events compared with placebo [61 ] and lowered the risk of major adverse car - diovascular events.”
Tang, X., Mao, C.-R., Fang, J., Ma, Z., Huang, Y., & Wang, D. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300538 · Cited by 4
Taha, H., Kandil, H., Badran, H. M., Farag, N. M., Khamis, H., Nasr, G. M., Samy, M., Abdrabou, M., Abuelezz, M., & Shaker, M. M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00562-7 · Cited by 5
Impact of payer rejections and out-of-pocket costs on patient access to bempedoic acid therapy
Hwang, J., Peterson, E. D., Gupta, A., Sarnes, E., Gillard, K. K., & Návar, A. M. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100940 · Cited by 5
Dodulík, J., Plášek, J., Kacířová, I., Uřinovská, R., Vrtal, J., & Václavík, J. (2025) · Pharmaceuticals · doi:10.3390/ph18060818 · Cited by 7
“The presence of SLCO1B1 c.521T > C polymorphism and variants in ABCB1 and CYP2C9 genes, detected in both cases, supports the hypothesis of impaired hepatic clearance contributing to systemic drug accumulation and toxicity [2,11].”
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date
Rizvi, A. A., Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Almahmeed, W. A., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2094771 · Cited by 4
Genome Editing in Dyslipidemia and Atherosclerosis
Chen, Z., Lehertshuber, C., & Schunkert, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_10 · Cited by 8
Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken?
Natale, F., Molinari, R., Franzese, R., Mollo, N., & Cimmino, G. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3020024 · Cited by 5
“The CLEAR Harmony trial involved 2230 patients with 1488 enrolled in the bempedoic acid treatment arm [44].”
BackgroundMethodInfluentialGier, C., Gilchrist, I. C., Fordham, M., Riordan, L., Milchan, E., Patel, N., Mojahedi, A., Choudhury, S., Kits, T., Cohen, R., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1284562 · Cited by 4
Management of Cardiovascular Disease in the Elderly
Onuorah, I., Agrawal, A., & WENGER, N. K. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_25 · Cited by 5
Arca, M., Pirillo, A., Gambacurta, R., Becker, C., Diamand, F., Ray, K. K., & Catapano, A. L. (2024) · European Atherosclerosis Journal · doi:10.56095/eaj.v3i3.76 · Cited by 4
“In the pivotal trial programme, bempedoic acid was shown to reduce LDL-C levels by ~ 17-18% in patients on statin therapy [17, 18] and by ~ 21-28% in patients intolerant to statins [19, 20].”
Self-citation2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid
Kim, H., Cha, J., & Lee, S. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.2.135 · Cited by 7
Bempedoic Acid: A Novel LDL Cholesterol–Lowering Agent
Shriver, K. (2020) · Clinical Diabetes · doi:10.2337/cd20-0038 · Cited by 4
Park, K., Vishnevetskaya, K., Vaidyanathan, J., Burckart, G. J., & Green, D. J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1973 · Cited by 4
Wagner, M., Leefmann, J., Künzel, S. R., Schmidt, M. M., & El‐Armouche, A. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1136-4356 · Cited by 4
“Unter maximal verträglicher Statin-Dosis führte die Gabe von Bempedoinsäure in der CLEAR-Harmony- und der CLEAR-Wisdom-Studie zu einer zusätzlichen LDL-C-Reduktion von 16,5 % bzw.”
InfluentialKaur, K. K. (2022) · Advances in Obesity Weight Management & Control · doi:10.15406/aowmc.2022.12.00367 · Cited by 6
Metadata
- Authors
- Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-14
- Volume
- 380
- Issue
- 11
- Pages
- 1022-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2922038538
- Cited by
- 807
- References
- 20
- Citations by year
- 2026: 77 · 2025: 87 · 2024: 114 · 2023: 143 · 2022: 116 · 2021: 107 · 2020: 107 · 2019: 53
- FWCI
- 91.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, LDL cholesterol lowering, ATP-citrate lyase inhibitor, hypercholesterolemia, atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, statin therapy, gout, adverse events, drug safety, lipid-lowering therapy, long-term treatment, gout risk, statin intolerance
- MeSH terms
- Aged, Apolipoproteins B, ATP Citrate (pro-S)-Lyase, C-Reactive Protein, Cholesterol, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Female, Humans, Hypercholesterolemia, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Peptide Fragments, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.